Together for the
Medicine of tomorrow
Medicine of tomorrow
We develop our projects in strategic partnerships – with our own know-how and a worldwide network in research, medicine and venture capital.
We are looking forward to new co-operations!
Together for the Medicine of tomorrow
We develop our projects in strategic partnerships – with our own know-how and a worldwide network in research, medicine and venture capital. We are looking forward to new co-operations!
A worldwide network of cooperation partners from public and industrial research institutions forms the backbone of many research projects of ISAR Bioscience and its scientists. Joint research and advancement of projects is one of our characteristics. In our collaborations, we attach great importance to maintaining the intellectual authorship of our partners and to playing a central role in their further development. In this way we want to achieve our common ambitious goals.
With some partners we work in loose co-operations, with others we enter into firm links – depending on the requirements of the respective project. Below you will find some examples of such alliances as well as information on our partners.
Technical University Munich
Institute of Pharmacology and Toxicology (Prof. Dr. Dr. Stefan Engelhardt)
The Institute of Pharmacology and Toxicology is part of the Biederstein Campus of the Technical University of Munich, which is located between the Munich district of Schwabing and the English Garden. The completely renovated building offers a large team of scientists and technical staff an ideal research infrastructure with modern laboratory space and high-quality scientific equipment.
The Research Institute for Translational Medicine is dedicated to the search for new therapeutics for cardiovascular diseases, which are still the main cause of death worldwide. The aim is to identify novel targets for drugs, analyze their function and develop innovative therapeutic strategies.
The institute also coordinates the Munich Heart Alliance. With this initiative, clinicians and scientists want to work together to improve the development of novel heart therapies. The Munich Heart Alliance is a partner location of the German Centre for Cardiovascular Research, DZHK.
Klinikum rechts der Isar
Clinic and Polyclinic for Internal Medicine I: Cardiology (Prof. Dr. Karl-Ludwig Laugwitz/Prof. Dr. Alessandra Moretti)
The clinic specializes in cardiology, angiology and pneumology, i.e. heart, vascular and lung diseases. Innovative therapies are used to treat circulatory disorders of the heart muscle and vessels, but also heart valve defects and cardiac arrhythmia as well as all lung diseases.
For many decades the clinic has been known for its successful basic and clinical science at a high level. It participates in a large number of clinical studies and thus makes an important contribution to the development of modern therapies and their safety.
A special focus is the Chair of Regenerative Medicine of Cardiovascular Diseases (Prof. Dr. Alessandra Moretti). The ambitious goal of this research is to develop regenerative therapeutic approaches such as the introduction of stem cells or differentiated cells derived from stem cells into the defective organ or the stimulation of endogenous regeneration processes. Numerous basic scientific questions still need to be answered before a successful translation can be achieved. The research group is working on this using state-of-the-art scientific methods.
Mainz University Medical Centre, Focus on Endocrinology and Metabolic Diseases
Autoimmune Endocrinology” Research Group (Prof. Dr. George Kahaly)
Together we want to improve the therapy of autoimmune diseases: the research teams of the renowned endocrinologist Professor George J. Kahaly from the University Medical Centre Mainz and researchers from ISAR Bioscience. Our main focus is on the widespread Graves’ disease. In this disease, the immune system produces antibodies against the patient’s own thyroid gland, which stimulates it to produce excessive amounts of its hormones, and to increase in size. Symptoms can also occur outside the thyroid gland, such as hormone-related disease of the eye cavity (endocrine orbitopathy). Many cases of hyperthyroidism cannot be controlled with medication alone: Often the diseased tissue must be destroyed by radioiodine therapy or surgically removed. There is a great need for innovative, effective and at the same time gentle forms of treatment.
Our two research teams have already developed corresponding approaches. Within the framework of this cooperation, we are now concentrating on certain immune cells, the T and B lymphocytes. We investigate their suitability as starting points for innovative therapies using mammalian disease models. We benefit from the novel Bio-Assays for the detection of Graves’ disease and the extensive experience with clinical studies in this field, which the endocrinologists from the University Medical Centre Mainz, Professor George Kahaly and Dr. Tanja Diana, bring to the cooperation with ISAR Bioscience.
Professor George Kahaly M.D., Ph.D., is a senior physician at the Department of Endocrinology and Metabolic Diseases at the I. Medical Clinic and Polyclinic of the University of Mainz. He directs the Endocrine and Thyroid Autoimmunity Program in the Endocrinology Outpatient Clinic, is Chair of the ORPHAN Expert Centre for Graves’ Orbitopathy and Autoimmune Polyendocrinopathy and directs the Molecular Thyroid Research Laboratory. George Kahaly has authored about 290 original articles and reviews. He has received numerous awards for his research, including the American Association of Clinical Endocrinologists / American College of Endocrinology (AACE/ACE) Endocrinology Award and the British Thyroid Association Medal (George Murray Award). Kahaly is co-editor of major journals and co-organiser of international congresses. He serves as a board member of the European Group of Graves’ Orbitopathy (EUGOGO) and has been active in various committees of the American Thyroid Association for many years.
Partners in biotechnology and industry
Lead Discovery Center (LDC), Dortmund and Planegg near Munich (Dr. Bert Klebl)
The Lead Discovery Center GmbH (LDC) was founded by Max Planck Innovation and the Max Planck Society to better exploit the potential of excellent basic research. The aim is to professionally transfer promising research projects into the development of new drugs.
With a team of experienced scientists, drug discovery experts and project managers in the working groups Medicinal Chemistry, Assay Development & Screening, Biology and Pharmacology, the LDC offers all services in the field of drug discovery – from target (biological target structure) to lead (chemical lead structure) – according to the highest industry standards. As an independent, commercially oriented company, the LDC collaborates with research institutions, universities and industry. It takes up promising research projects at early stages of development and jointly develops them further into active pharmaceutical ingredients that already provide proof-of-concept in animal studies.
The mission of AssayWorks is to accelerate the research programs of partners by developing and performing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. AssayWorks combines scientific rigor with its expertise in laboratory automation, informatics and industrial processes to transform sophisticated assays into quantitative, reproducible results.